embecta Announces Second Quarter 2022 Earnings Conference Call Information
Rhea-AI Summary
Embecta Corp. (NASDAQ: EMBC) announced it will release its financial results for Q2 of fiscal 2022 on May 13, 2022, before market opening. A conference call is set for 8:00 AM ET to discuss the results, provide business updates, and share financial guidance for 2022. Participants can join via phone or a live webcast on the company's investor website. An audio replay will be available post-call. Embecta, focused on diabetes care, leverages a century of insulin delivery experience to support individuals with diabetes.
Positive
- None.
Negative
- None.
News Market Reaction – EMBC
On the day this news was published, EMBC declined 4.15%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
FRANKLIN LAKES, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ: EMBC) today announced that it will report its financial results for the second quarter of fiscal year 2022 before the market opens on Friday, May 13, 2022.
Management will host a conference call at 8:00 a.m. Eastern Time (ET) on May 13 to discuss the results of the quarter, provide an update on its business, including financial guidance for 2022, and host a question and answer session.
Those who would like to participate may dial 800-374-1601 (U.S.) or 210-787-4744 (International) and provide access code 5596984. The call can also be accessed through a live webcast on the company's website at investors.embecta.com.
An audio replay of the call will be available beginning at 11:00 a.m. ET on May 13, 2022, either on the embecta website or by telephone. The replay can be accessed by dialing 855-859-2056 (U.S.), or 404-537-3406 (International). The access code is 5596984. The webcast will be archived on the investor website for one year.
About embecta
embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.
CONTACTS
Investors:
Contact IR